Edition:
United Kingdom

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

3.17USD
19 Jul 2018
Change (% chg)

$0.19 (+6.38%)
Prev Close
$2.98
Open
$3.00
Day's High
$3.23
Day's Low
$3.00
Volume
24,719
Avg. Vol
22,317
52-wk High
$27.83
52-wk Low
$2.94

Chart for

About

Arsanis, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and... (more)

Overall

No Ratios Available.

Financials

  ASNS.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -- -- --
ROI: -- 2.21 14.61
ROE: -- 3.85 16.34

BRIEF-Arsanis Posts Qtrly Loss Per Share $0.74

* ASN100 PHASE 2 TRIAL INTERIM ANALYSIS RESULTS EXPECTED IN LATE JUNE

10 May 2018

BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies

* BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

04 Apr 2018

BRIEF-Arsanis Granted Key Patents For ASN100 Covering Cross-Neutralizing S. Aureus Toxin Antibodies

* ARSANIS GRANTED KEY PATENTS FOR ASN100 COVERING CROSS-NEUTRALIZING S. AUREUS TOXIN ANTIBODIES Source text for Eikon: Further company coverage:

14 Mar 2018

BRIEF-Arsanis Reports Q4 Net Loss $1.68 Per Share

* ARSANIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2017

09 Mar 2018

Earnings vs. Estimates